Laurence Cocquerel

List of Publications by Year in Descending Order

48	2,676	27	51
papers	citations	h-index	g-index
52	2,903	5.8	4.38
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
48	Processing and Subcellular Localization of the Hepatitis E Virus Replicase: Identification of Candidate Viral Factories.. *Frontiers in Microbiology*, **2022**, 13, 828636	5.7	3
47	In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus. *In Silico Pharmacology*, **2021**, 9, 35	4.3	4
46	New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle. *Scientific Reports*, **2019**, 9, 6243	4.9	22
45	Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. *Journal of Infectious Diseases*, **2019**, 220, 811-819	7	13
44	Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. *Journal of Virology*, **2018**, 92,	6.6	9
43	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. *Gastroenterology*, **2018**, 154, 211-223.e8	13.3	85
42	Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses. *Journal of General Virology*, **2018**, 99, 1086-1096	4.9	15
41	Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication. *Cellular Microbiology*, **2018**, 20, e12804	3.9	19
40	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. *Gut*, **2017**, 66, 920-929	19.2	85
39	Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. *Journal of Virology*, **2016**, 90, 8422-34	6.6	24
38	New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. *Journal of Virology*, **2015**, 89, 8346-64	6.6	15
37	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. *PLoS ONE*, **2015**, 10, e0142539	3.7	7
36	SRFBP1, an Additional Player in HCV Entry. *Trends in Microbiology*, **2015**, 23, 590-593	12.4	1
35	CD81 and hepatitis C virus (HCV) infection. *Viruses*, **2014**, 6, 535-72	6.2	61
34	Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. *PLoS ONE*, **2014**, 9, e111333	3.7	16
33	EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry. *Cellular Microbiology*, **2013**, 15, 1234-52	3.9	34
32	The antimalarial ferroquine is an inhibitor of hepatitis C virus. *Hepatology*, **2013**, 58, 86-97	11.2	41

31	The Role of CD81 in HCV and Plasmodium Infection **2013**, 345-386		
30	Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81. *Journal of Virology*, **2012**, 86, 9606-16	6.6	37
29	Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies. *Experimental Cell Research*, **2011**, 317, 2683-94	4.2	0
28	Hepatitis C virus entry into the hepatocyte. *Open Life Sciences*, **2011**, 6, 933-945	1.2	7
27	Interacting regions of CD81 and two of its partners, EWI-2 and EWI-2wint, and their effect on hepatitis C virus infection. *Journal of Biological Chemistry*, **2011**, 286, 13954-65	5.4	48
26	The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry. *BMC Microbiology*, **2009**, 9, 111	4.5	33
25	The Ig domain protein CD9P-1 down-regulates CD81 ability to support Plasmodium yoelii infection. *Journal of Biological Chemistry*, **2009**, 284, 31572-8	5.4	20
24	Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. *Cellular Microbiology*, **2008**, 10, 606-17	3.9	69
23	Early steps of the hepatitis C virus life cycle. *Cellular Microbiology*, **2008**, 10, 821-7	3.9	95
22	The CD81 partner EWI-2wint inhibits hepatitis C virus entry. *PLoS ONE*, **2008**, 3, e1866	3.7	82
21	Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. *Journal of General Virology*, **2007**, 88, 2495-2503	4.9	128
20	Hepatitis C virus entry: potential receptors and their biological functions. *Journal of General Virology*, **2006**, 87, 1075-1084	4.9	150
19	Kinetics of HCV envelope proteinsWinteraction with CD81 large extracellular loop. *Biochemical and Biophysical Research Communications*, **2005**, 328, 1091-100	3.4	21
18	Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. *Journal of Biological Chemistry*, **2004**, 279, 41384-92	5.4	52
17	Characterization of functional hepatitis C virus envelope glycoproteins. *Journal of Virology*, **2004**, 78, 2994-3002	6.6	184
16	CD81-dependent binding of hepatitis C virus E1E2 heterodimers. *Journal of Virology*, **2003**, 77, 10677-83	6.6	75
15	Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. *Journal of Virology*, **2003**, 77, 1604-9	6.6	38
14	Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. *EMBO Journal*, **2002**, 21, 2893-902	13	95

13	Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line. *Glycobiology*, **2002**, 12, 95-101	5.8	19
12	Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. *Journal of Virology*, **2002**, 76, 3720-30	6.6	164
11	Biogenesis of hepatitis C virus envelope glycoproteins. *Journal of General Virology*, **2001**, 82, 2589-2595	4.9	121
10	Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2. *Journal of General Virology*, **2001**, 82, 1629-1635	4.9	37
9	The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. *Journal of Biological Chemistry*, **2000**, 275, 31428-37	5.4	124
8	Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein. *Journal of Biological Chemistry*, **2000**, 275, 30605-9	5.4	44
7	Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. *Journal of Virology*, **2000**, 74, 3623-33	6.6	139
6	The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. *Journal of Virology*, **1999**, 73, 2641-9	6.6	126
5	Endoplasmic reticulum retention of hepatitis C virus glycoprotein complex E1E2: A role for the transmembrane domain of E2. *Biology of the Cell*, **1998**, 90, 118-118	3.5	
4	Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. *Journal of Biological Chemistry*, **1998**, 273, 32088-95	5.4	118
3	A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. *Journal of Virology*, **1998**, 72, 2183-91	6.6	193
2	The Endocytic Recycling Compartment Serves as a Viral Factory for Hepatitis E Virus		1
1	The fate of Hepatitis E virus capsid protein is regulated by an Arginine-Rich Motif		2